Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Can diet, microbiome personalization reverse IBD increase?

Key clinical point: Personalized diet may stem the global spread of inflammatory bowel disease.

Major finding: Pouchitis is a viable surrogate for studying diet and microbiome in inflammatory bowel disease.

Study details: A prospective cohort study of an unspecified number of patients with pouchitis.

Disclosures: Dr. Dotan reported financial relationships with AbbVie, Takeda, Pfizer, Genentech/Roche, Neopharm, and Gilead.

Citation:

Dotan I. Crohn’s & Colitis Congress 2020, Presentation Sp75.